This is a working overview of Lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
== Composition == Salcatonin is composed of 32 amino acids, of which 13 differ from human calcitonin. The structure of human calcitonin and salcatonin is as follows: Human calcitonin: H-Cys1-Gly-Asn-Leu-Ser-Thr-Cys7-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-lle-Gly-Val-Gly-Ala-Pro-NH2 Salcatonin: H-Cys1-Ser-Asn-Leu-Ser-Thr-Cys7-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 The cysteine in the first and seventh positions form a disulfide bond.
By 1913, Japan was producing 672 million pounds of yarn per year, becoming the world's fourth-largest exporter of cotton yarn. The first railway was opened between Tokyo and Yokohama in 1872. The railway system was rapidly developed throughout Japan well into the twentieth century. The introduction of railway transportation led to more efficient production due to the decrease in transport costs, allowing manufacturing firms to move into more populated interior regions of Japan in search for labor input. The railway also enabled newfound access to raw materials that had previously been too difficult or too costly to transport. There were at least two reasons for the speed of Japan's modernization: the employment of more than 3,000 foreign experts (called o-yatoi gaikokujin or 'hired foreigners') in a variety of specialist fields such as teaching foreign languages, science, engineering, the army and navy, among others; and the dispatch of many Japanese students overseas to Europe and America, based on the fifth and last article of the Charter Oath of 1868: 'Knowledge shall be sought throughout the world so as to strengthen the foundations of Imperial rule.' The process of modernization was closely monitored and heavily subsidized by the Meiji government, enhancing the power of the great zaibatsu conglomerate business firms such as Mitsui and Mitsubishi.
At New York Presbyterian Hospital, part of Columbia University Medical Center in New York, NY, a study was conducted on the significant rise in carbapenem resistance in K. pneumoniae from 1999 to 2007. Following a positive blood culture from a patient, overall mortality was 23% in 7 days, 42% in 30 days, and 60% by the end of hospitalization. The overall in-hospital mortality rate was 48%. At Soroka Medical Center, an Israeli university teaching hospital, a study was done between October 2005 and October 2008 to determine the direct mortality rate associated with carbapenem-resistant K. pneumoniae bloodstream infections. The crude mortality rate for those with the resistant bacteremia was 71.9%, and the attributable mortality rate was determined to be 50% with a 95% confidence interval. The crude mortality rate for control subjects was 21.9%. As a result of the study, Soroka Medical Center started an intensive program designed to prevent the spread of carbapenem-resistant K. pneumoniae. A 2013 retrospective study at the Shaare Zedek Medical Center of patients with urinary tract infections (bacteriuria) caused by carbapenem-resistant Klebsiella pneumoniae (CRKp) showed no statistically significant difference in mortality rates from patients with bacteriuria caused by carbapenem-susceptible K. pneumoniae (CSKp). A 29% mortality rate was seen in patients with CRKp infection compared to a 25% mortality rate in patients with CSKp infections that produced extended-spectrum beta-lactamase (ESBL).
== Annual reconstitution == Russell rebalances its indexes once each year in June, called "reconstitution". The reconstitution consists of updating the global list of investable stocks and assigning them to the appropriate indices. The Russell indexes do not immediately replace a company that merges with another firm or has its stock delisted. However, Russell adds initial public offerings (IPOs) on a quarterly basis, capturing these stocks in a systematic way. Abnormal trading volumes caused by index fund managers re-balancing their portfolios has a history of significant market impact during the last few seconds before the New York Stock Exchange and NASDAQ closing prices are determined. The index rebalance is typically scheduled for the closing price on the last Friday in June.
Sources: en.wikipedia.org
=== Pharmacokinetics === Since imidazolines are sympathomimetic agents, their primary effects appear on α adrenergic receptors, with little if any effect on β adrenergic receptors. Like other imidazolines, Oxymetazoline is readily absorbed orally. Effects on α receptors from systemically absorbed oxymetazoline hydrochloride may persist for up to 7 hours after a single dose. The elimination half-life in humans is 5–8 hours. It is excreted unchanged both by the kidneys (30%) and in feces (10%).
The three substrates of this enzyme are (2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinic acid, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are (S)-2,3,4,5-tetrahydrodipicolinic acid], oxidised NAD+ and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is part of the biosynthesis pathway to lysine.
Total production from fishing in North and Baltic Seas was 40 780 tonnes in 2019, ca. 1/3 German production. In the Baltic Sea total production amounted to 10377 tonnes (2019), of which 5432 tonnes of sprat, 2568 tonnes of flatfish and 1190 tonnes of cod. In the North Sea the numbers were 19,487 tonnes of mussels, 3560 tonnes of North Sea shrimp, 1166 tonnes of herring and 7062 other fishes. One important aquaculture product is mussels, 16864 tonnes. Inland fishing and aquaculture are not significant, with 221 and 250 tonnes in 2019, respectively.
Sources: en.wikipedia.org
== Chemistry == Radium only exhibits the oxidation state of +2 in solution. It forms the colorless Ra2+ cation in aqueous solution, which is highly basic and does not form complexes readily. Most radium compounds are therefore simple ionic compounds, though participation from the 6s and 6p electrons (in addition to the valence 7s electrons) is expected due to relativistic effects and would enhance the covalent character of radium compounds such as RaF2 and RaAt2. For this reason, the standard electrode potential for the half-reaction Ra2+ (aq) + 2e- → Ra (s) is −2.916 V, even slightly lower than the value −2.92 V for barium, whereas the values had previously smoothly increased down the group (Ca: −2.84 V; Sr: −2.89 V; Ba: −2.92 V). The values for barium and radium are almost exactly the same as those of the heavier alkali metals potassium, rubidium, and caesium.
== Major neuroendocrine systems == Hypothalamic–pituitary–adrenal axis (HPA axis) Hypothalamic–pituitary–thyroid axis (HPT axis) Hypothalamic–pituitary–gonadal axis (HPG axis) Hypothalamic–neurohypophyseal system
=== Post-peptide modifications === The modification required to biosynthesize mature chloroeremomycin include: oxidative cross-linking of aromatic rings, hydroxylation and chlorination of the two Tyr residues, methylation of Leu, and glycosylation at aa4 and aa6. The oxidative crosslinks are catalyzed by enzymes OxyA-C. The glycosylations are catalyzed by enzymes GtfA-C (coded by Orf11-13 respectively). The chlorinations are performed by enzymes encoded by Orf10 and 18.
== Vertebrates == Tendon cells, or tenocytes, are elongated fibroblast type cells. The cytoplasm is stretched between the collagen fibres of the tendon. They have a central cell nucleus with a prominent nucleolus. Tendon cells have a well-developed rough endoplasmic reticulum and they are responsible for synthesis and turnover of tendon fibres and ground substance.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.